Breakthrough: EU Approves Oral BTK Inhibitor Tolebrutinib as First Disability-Targeting Therapy for Nonrelapsing SPMS

August 17, 2026

NeurologyLive Europe

Overview

The European Commission has approved Sanofi’s oral, brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor, tolebrutinib (Cenrifki), for nonrelapsing secondary progressive multiple sclerosis (SPMS). This approval, based on Phase 3 HERCULES study results, marks the first therapy specifically designed to target disease progression and disability in this patient population, addressing a critical unmet medical need.

In Depth

Background

Multiple sclerosis (MS) is a chronic, inflammatory autoimmune disease affecting the central nervous system (CNS). Approximately half of all MS patients eventually progress to secondary progressive MS (SPMS), a form characterized by continuous neurological decline independent of relapses. For individuals with ‘nonrelapsing’ SPMS, therapeutic options specifically targeting disease progression have historically been severely limited. The recent approval of tolebrutinib addresses this significant unmet medical need, providing an effective oral treatment that marks a pivotal advancement in the MS treatment paradigm and reinforces the emerging role of BTK inhibitors in this complex disease.

Key Findings

The European Commission has granted formal approval for tolebrutinib (brand name: Cenrifki), an oral, brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi. This approval is specifically for the treatment of nonrelapsing secondary progressive multiple sclerosis (SPMS), following a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2026. This landmark decision is supported by robust efficacy and safety data from the Phase 3 HERCULES study. Tolebrutinib is notable as the first therapy expressly designed to target disease progression in this challenging indication, signifying a major breakthrough for patients facing significant unmet medical needs.

Technical / Clinical Details

Tolebrutinib operates as a small molecule, reversible inhibitor of Bruton’s tyrosine kinase (BTK). BTK is an enzyme critical to various cellular processes, including B-cell activation, differentiation, and proliferation, as well as microglial activation – all pathways deeply implicated in the pathophysiology of multiple sclerosis. Its brain-penetrant properties are key; tolebrutinib is designed to cross the blood-brain barrier (BBB) and directly engage with targets within the central nervous system (CNS). This mechanism aims to suppress brain inflammation and, consequently, slow neurodegeneration and overall disease progression. The pivotal Phase 3 HERCULES study validated this approach, demonstrating a statistically significant effect of tolebrutinib in slowing disease progression in nonrelapsing SPMS patients compared to placebo. Key outcomes included observed delays in disability progression and reductions in brain atrophy, alongside a manageable safety profile. This success highlights the critical importance and potential of CNS-penetrant therapeutics for complex neurological conditions.

Strategic Significance & Outlook

The European approval of tolebrutinib is poised to significantly enhance the quality of life for patients with nonrelapsing SPMS by potentially slowing the long-term progression of disability. This regulatory milestone is expected to catalyze further research into BTK inhibitors for other progressive MS subtypes, as well as broader inflammatory and neurodegenerative conditions of the CNS. Sanofi has indicated plans for a global rollout, with anticipated approval processes in other key regions being closely monitored. Should tolebrutinib become a new standard of care in MS treatment, it will undoubtedly intensify competition within the pharmaceutical landscape for BTK inhibitors, potentially spurring the development of even more advanced and innovative therapeutic solutions. Ultimately, this breakthrough promises improved outcomes for a critically vulnerable patient population.

Source: https://www.neurologylive.com/view/tolebrutinib-approved-eu-nonrelapsing-secondary-progressive-ms-marking-first-disability-targeting-therapy-indication

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.